SCHEMBL6408845

SCHEMBL6408845

CC(C)Oc1ccc(Br)cc1CO

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.53
ALDH1A1 P00352 5/20 0.45
LMNA P02545 3/20 0.45
MAPT P10636 3/20 0.45
NPC1 O15118 3/20 0.43
HTT P42858 2/20 0.43
POLB P06746 1/20 0.43
ALOX12 P18054 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HSD17B10 Q99714 2/20 0.42
MAPK1 P28482 1/20 0.42
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
CCR5 P51681 1/20 0.38
USP2 O75604 1/20 0.38
GAA P10253 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3991129 0.84 ALDH1A1 (0.41) PTGDR2ALDH1A1LMNAMAPTHTT
SCHEMBL16959585 0.82 PTGDR2 (0.53) PTGDR2ALDH1A1LMNAMAPTNPC1
SCHEMBL27572441 0.82 ALDH1A1 (0.40) PTGDR2ALDH1A1LMNAMAPTHTT
SCHEMBL12180330 0.80 FFAR4 (0.48) ALDH1A1LMNAMAPTPOLBSMN1; SMN2
SCHEMBL1145684 0.79 PTGDR2 (0.57) PTGDR2ALDH1A1LMNAMAPTHTT
SCHEMBL15054484 0.79 PTGDR2 (0.58) PTGDR2ALDH1A1LMNAMAPTNPC1
SCHEMBL29130068 0.79 PTGDR2 (0.50) PTGDR2ALDH1A1LMNAMAPTNPC1
SCHEMBL29029436 0.79 PTGDR2 (0.61) PTGDR2ALDH1A1LMNAMAPTNPC1
SCHEMBL13903647 0.79 PTGDR2 (0.50) PTGDR2ALDH1A1LMNAMAPTNPC1
SCHEMBL16950499 0.79 MAPT (0.53) MAPTSMN1; SMN2GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287060-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-08-29 US disclosed
EP-4301752-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Cambridge Enterprise Limited (GB) 2024-01-10 EP disclosed
US-11866436-B2 Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-01-09 US disclosed
CN-117295736-A Benzo [ C ] [2,6] naphthyridine derivatives, compositions thereof and therapeutic uses thereof 剑桥实业有限公司 2023-12-26 CN disclosed
US-20230250097-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Apollo Therapeutics Limited (GB) 2023-08-10 US disclosed
US-20230250097-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Apollo Therapeutics Limited (GB) 2023-08-10 US disclosed
US-20230250097-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF Apollo Therapeutics Limited (GB) 2023-08-10 US disclosed
WO-2022185041-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2022-09-09 WO disclosed
EP-2900645-A1 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION Bayer CropScience AG (DE) 2015-08-05 EP disclosed
US-20050038072-A1 Nitrogeneous cyclic ketone derivative, process for producing the same, and use TAKEDA CHEMICAL INDUSTRIES, LTD. 2005-02-17 US disclosed
EP-1460062-A1 NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250097-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CSNK1A1, CSNK1D, CSNK2A1 PTGDR2 1987/4885ALDH1A1 2913/4885LMNA 1058/4885
US-11866436-B2 Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof ABCB11, CEL, NDC1 PTGDR2 2046/4885ALDH1A1 681/4885LMNA 438/4885
US-20240287060-A1 BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF CSNK1A1, CSNK1D, CSNK2A1 PTGDR2 1987/4885ALDH1A1 2913/4885LMNA 1058/4885
US-20050038072-A1 Nitrogeneous cyclic ketone derivative, process for producing the same, and use BDKRB1, BDKRB2, TACR1 PTGDR2 108/4885ALDH1A1 1984/4885LMNA 4687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.